Intellia Corp (NTLA) Long-Term Debt to Capital Ratio
Intellia Therapeutics (NTLA) is developing cutting-edge treatments through genome editing, yet faces patent conflicts and uncertainty regarding test outcomes. Geopolitical fragmentation and sanctions complicate biomaterial logistics and global research. Meanwhile, the business relies on an autonomous demand cycle, remaining a defensive asset during recessions. The linear price action on the GURU.Markets chart confirms this data, where the indicator stands at 0.07.
Analytical breakdowns for Intellia Therapeutics (NTLA)
- current price and projected stock value:
- market capitalization details:
- issuer book value statistics:
- debt and solvency information:
Debt to Equity Ratio Intellia Therapeutics|NTLA - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio intelliatx.com|NTLA - Company Aggregate Debts|Debts to Book Value Intellia Therapeutics, Inc.|NTLA - Company Long-Term Debt|Company Short-Term Debt Intellia Therapeutics|Quick Liquidity intelliatx.com
- net income and valuation ratios data:
Summary company analysis:NTLA (Intellia Therapeutics Inc)
This ratio determines the degree of financial leverage by comparing liabilities with a maturity of over one year to equity to assess long-term solvency. The current long-term debt-to-equity ratio is critical for Intellia Therapeutics (NTLA), as the biotech's lack of commercial products and operating losses make it dependent on external borrowings to fund clinical trials.
Analysis of competing companies
Long-Term Debt to Capital Ratio TEM (Tempus)|Long-Term Debt to Equity Qiagen Group (QGEN)|Isis Pharmaceuticals - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital RGEN (Repligen Corporation)|Long-Term Debt to Capital aviditybiosciences.com RNA|CRISPR Therapeutics - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital GeneDx Holdings WGS|Ultragenyx Pharma (RARE) - Long-Term Debt to Equity|Long-Term Debt to Capital Ratio BEAM|Long-Term Debt to Equity Ratio SRPT|TWST (twistbioscience.com) - Long-Term Loans to Capital Ratio|Long-Term Debt to Capital TXG|STOK - Long-Term Liabilities to Capital|Long-Term Debt to Equity BioLife Corp BLFS|Wave Pharma - Long-Term Debt to Equity|MAZE - Long-Term Debt to Equity|SION: Long-Term Debt to Equity|PRME: Long-Term Debt to Capital|TSHA - Ratio of Long-Term Indebtedness to Capital|QURE (uniQure Corp) - Long-Term Debt to Capital|Long-Term Debt to Capital MeiraGTx Corp|Long-Term Debt to Equity Ratio RGNX (REGENXBIO Inc.)|SLDB (solidbio.com) - Long-Term Debt to Capital Coefficient|Ocugen - Long-Term Debt to Equity Ratio|Long-Term Loans to Capital Ratio PACB (Pacific Biosciences of California, Inc.)|Benitec - Long-Term Debt to Capital|Long-Term Debt to Capital Coefficient DSGN (Design Corp)|RCKT: Long-Term Debt to Capital|Long-Term Liabilities to Capital 4dmoleculartherapeutics.com (FDMT)|Long-Term Debt to Equity Lexeo Therapeutics Inc.|KRRO: Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital EDIT|Long-Term Debt to Capital Silence Therapeutics Corp (SLN)|Long-Term Debt to Equity ProQR Therapeutics PRQR|CDXS (Codexis Inc) - Long-Term Liabilities to Equity|Sangamo Therapeutics, Inc. - Long-Term Debt to Capital|Long-Term Liabilities to Capital Nautilus Biotechnology|MGX (Metagenomi, Inc) - Long-Term Debt to Equity Ratio|Precision BioSciences Inc. (DTIL) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio GBIO|BOLD (boundlessbio.com) - Long-Term Loans to Capital Ratio|Long-Term Debt to Capital XCUR|Ratio of Long-Term Indebtedness to Capital imunon.com|Long-Term Debt to Capital PHIO (Phio Pharmaceuticals Corp.)|MBIO - Long-Term Debt to Equity Ratio|RNAZ - Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital Bionano Genomics, Inc. BNGO|Applied DNA Sciences, Inc. (APDN) - Long-Term Debt to Equity|Long-Term Debt to Capital Ratio BLUE|Long-Term Debt to Equity Ratio IPA|OMGA (Omega Therapeutics Corp) - Long-Term Loans to Capital Ratio|Long-Term Debt to Equity Singular Genomics Systems (OMIC)|Long-Term Debt to Equity RGLS (regulusrx.com)|Long-Term Debt to Capital SYRS (Syros Pharmaceuticals, Inc.)|Long-Term Debt to Capital Telesis Bio Inc. TBIO|TRACON - Long-Term Debt to Capital|UBX (Unity Biotechnology, Inc) - Long-Term Debt to Capital Ratio